*Investigators proposing concepts for in-kind preclinical testing should complete Part A, providing sufficient detail to enable review. Concept reviewers are to complete Part B.*

**PART A. PROPOSAL**

**CONCEPT OVERVIEW**

|  |  |
| --- | --- |
| Agent(s) |  |
| Mechanism of Action |  |
| Manufacturer |  |
| Study Type Proposed | In vitro  In vivo (*please check one*) |

**INVESTIGATOR**

|  |  |
| --- | --- |
| Name |  |
| Position |  |
| Company/Institution |  |
| Contact Email |  |

**RATIONALE**

*Describe the biological rationale supporting the proposed therapeutic strategy in chordoma, and how/why it can become standard of care given other available options (suggested 1/2 page)*

**PRELIMINARY DATA**

*Explain the molecular, preclinical and/or clinical evidence that justifies evaluating the proposed therapy for chordoma. This can be preliminary data in chordoma or related cellular contexts (1/2 page max)*

**AVAILABILITY OF THERAPY**

*Discuss the plan for securing a supply of therapy from the manufacturer or commercial resource (1-2 sentences max)*

**STUDY DESIGN**

*Describe and briefly justify the design of the proposed study, including model selection, number of arms, dosing regimen, endpoints, end-of-study sample collections and any associated analyses*

**FUTURE PLANS**

*Assuming this concept looks promising, i) specify your intent to publish the data, and ii) outline a potential path to clinical testing of this concept, along with any anticipated hurdles (1 paragraph max)*

**EVIDENCE FOR THERAPEUTIC WINDOW**

*Discuss the likelihood of the therapy being well-tolerated at doses that can achieve efficacy, both in mice and in humans. State whether there is existing evidence for tolerability of the proposed regimen in athymic nude mice (1 paragraph max)*

**PATIENT POPULATION**

*Indicate which (and what % of) chordoma patients are most likely to benefit from this therapy, and/or the plan for evaluating the patient selection strategy (1 paragraph max)*

**PART B. REVIEW** [this section to be completed by concept reviewer]

*Use the information provided above to evaluate the strength of the proposed therapeutic strategy and assess whether in-kind preclinical testing is warranted.*

|  |  |
| --- | --- |
| Reviewer Name |  |
| Decision | Accept  Reject |

**RATIONALE**

*Briefly describe the reason for your decision (1 paragraph max). For in vivo proposals with compelling rationale that are rejected due to insufficient preliminary data, clearly note whether additional in vitro testing is recommended.*